Dibenol5 mg

Approved Use

Dibenol is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Combination Therapy

Dibenol is also used, under a physician's supervision, in combination with metformin or other antidiabetic agents when diet, exercise, and a single agent do not achieve adequate glycemic control.

Dibenol is not indicated for type 1 diabetes mellitus or diabetic ketoacidosis, which require insulin therapy.

Each tablet contains Glibenclamide (also known as glyburide) as the active ingredient, commonly available in strengths of 2.5 mg and 5 mg for oral administration. Tablets also contain standard pharmaceutical excipients such as binders, fillers, and disintegrants.

Dibenol is an oral, second-generation sulfonylurea used to lower blood glucose levels in adults with type 2 diabetes mellitus. It works mainly by stimulating the pancreas to release more insulin.

Dibenol is intended for use alongside diet control and regular physical activity, and it is one of the longer-acting sulfonylureas available, generally taken once or twice daily.

Dibenol belongs to the sulfonylurea class of oral antidiabetic (hypoglycemic) agents, specifically the second-generation sulfonylureas.

Mechanism of Action

Glibenclamide lowers blood glucose acutely by stimulating the release of insulin from the beta cells of the pancreas. It binds to the sulfonylurea receptor (SUR1) on pancreatic beta-cell ATP-sensitive potassium channels, causing the channels to close, the cell membrane to depolarize, and calcium to enter the cell — this triggers insulin secretion.

With long-term use, the blood glucose-lowering effect of Glibenclamide appears to persist even as the acute insulin-releasing response declines, suggesting additional extrapancreatic (peripheral tissue insulin sensitivity) effects.

Pharmacokinetics

Glibenclamide is well absorbed orally, extensively bound to plasma proteins, metabolized in the liver, and has a relatively long duration of action, which allows once- or twice-daily dosing.

Dibenol tablets should be taken by mouth with breakfast or the first main meal of the day, at approximately the same time each day. Swallow the tablet with a glass of water; do not skip meals after taking Dibenol, as this increases the risk of hypoglycemia (low blood sugar). If a dose is missed, it should not be doubled — consult a physician or pharmacist for guidance.

Drugs That May Increase the Risk of Hypoglycemia with Dibenol

• NSAIDs, salicylates, and sulfonamides (displace protein binding)
• ACE inhibitors, fluconazole, fluoxetine, clarithromycin
• Fluoroquinolone antibiotics
• Non-selective beta-blockers (may also mask warning signs of hypoglycemia)
• Alcohol (may also cause a disulfiram-like reaction and prolonged hypoglycemia)
• Monoamine oxidase inhibitors (MAOIs)

Drugs That May Reduce the Effectiveness of Dibenol

• Thiazide and other diuretics, corticosteroids, oral contraceptives, and thyroid hormones (raise blood glucose)
• Rifampin (induces metabolism of Dibenol, reducing its effect)

Other Notable Interactions

• Bosentan: co-administration with Dibenol is generally avoided due to reports of elevated liver enzymes.
• Colesevelam: reduces absorption of Dibenol; Dibenol should be taken at least 4 hours before colesevelam.
• CYP2C9 and CYP3A4 inhibitors or inducers may alter blood levels of Dibenol and require glucose monitoring.

Most Significant Risk

Hypoglycemia is the principal and most important adverse effect of Dibenol; severe episodes with coma, seizure, or other neurological impairment occur infrequently but can be serious, particularly because Dibenol has a long duration of action (see Precautions and Overdose).

Common

• Nausea, epigastric fullness, heartburn
• Weight gain
• Transient blurred vision (related to blood glucose fluctuations)

Less Common / Rare

• Skin reactions: pruritus, erythema, urticaria, rare photosensitivity
• Blood disorders: leukopenia, thrombocytopenia, hemolytic anemia (particularly in G6PD-deficient patients, see Precautions)
• Hyponatremia and syndrome of inappropriate antidiuretic hormone secretion (SIADH)
• Cholestatic jaundice, elevated liver enzymes (rare)

Pregnancy

Dibenol should be used during pregnancy only if the potential benefit clearly justifies the potential risk to the fetus; insulin is generally the preferred treatment for diabetes during pregnancy to achieve tight glucose control. If a sulfonylurea such as Dibenol is used, it is typically discontinued at least two weeks before the expected delivery date, since prolonged, severe neonatal hypoglycemia has been reported in infants of mothers who received a sulfonylurea near delivery. Consult a physician before use during pregnancy.

Lactation

It is not known whether Dibenol passes into human breast milk; because of the potential for neonatal hypoglycemia, a decision should be made, in consultation with a physician, whether to discontinue nursing or discontinue Dibenol, taking into account the importance of the drug to the mother.

Hypoglycemia

All sulfonylureas, including Dibenol, can cause severe hypoglycemia. Because Dibenol has a long duration of action, hypoglycemia may be prolonged and severe, especially in elderly patients, those with irregular meal patterns, or those with renal or hepatic impairment. Patients should be educated to recognize and manage hypoglycemia (sweating, tremor, confusion, hunger) promptly.

Renal and Hepatic Impairment

Use Dibenol with extra caution, at a lower starting dose, in patients with renal or hepatic impairment; significant impairment often favors avoiding Dibenol in favor of a shorter-acting antidiabetic agent because of the increased risk of prolonged hypoglycemia.

Elderly Patients

Elderly patients are at higher risk of severe, prolonged hypoglycemia with Dibenol; a shorter-acting sulfonylurea or alternative agent is often preferred in this population.

G6PD Deficiency

Dibenol and other sulfonylureas may cause hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency; a non-sulfonylurea alternative should be considered in these patients.

Cardiovascular Safety

Older studies raised concern about a possible increase in cardiovascular mortality with sulfonylureas compared with diet alone or other treatments; this should be discussed with patients as a precaution when considering Dibenol therapy, though it is not an absolute contraindication.

Loss of Blood Glucose Control

The effectiveness of Dibenol may diminish over time or during periods of stress, fever, trauma, surgery, or infection; temporary insulin therapy may be required.

Overdose of Dibenol primarily causes hypoglycemia, which may present as sweating, tremor, palpitations, confusion, hunger, weakness, and in severe cases, seizures, coma, or neurological impairment.

Mild hypoglycemia can often be treated promptly with oral glucose or sugar. However, any suspected Dibenol overdose or severe/prolonged hypoglycemia is a medical emergency — seek immediate medical attention or contact emergency services / a poison control center right away. Hospitalization and close monitoring (often for 24–48 hours) may be required, as hypoglycemia can recur after apparent recovery due to the long duration of action of Dibenol. Do not attempt to manage severe hypoglycemia from Dibenol overdose at home without professional medical guidance.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal Impairment

Use Dibenol with caution and at reduced starting doses; significant renal impairment increases the risk of prolonged hypoglycemia and often warrants an alternative agent (see Precautions).

Hepatic Impairment

Use Dibenol with caution and close monitoring, as impaired hepatic metabolism can prolong its glucose-lowering effect and increase hypoglycemia risk.

Elderly

Start at the lowest effective dose (e.g., 1.25 mg daily) due to increased sensitivity to the hypoglycemic effects of Dibenol (see Precautions).

Pediatric Patients

Safety and efficacy of Dibenol in children have not been established; its use in this population is not recommended (see Pediatric Uses).

Pregnancy and Breastfeeding

See Pregnancy and Lactation section above.

Dibenol is generally used as a long-term, ongoing treatment for type 2 diabetes mellitus, alongside diet and exercise. Treatment duration and dose are determined and periodically reassessed by the treating physician based on blood glucose control (e.g., HbA1c), tolerability, and any changes in kidney or liver function.

Sulfonylureas (second-generation); Oral antidiabetic (hypoglycemic) agents. Glibenclamide is classified within this drug class.

Glibenclamide acts primarily by binding to sulfonylurea receptors (SUR1) on pancreatic beta-cell ATP-sensitive potassium (K-ATP) channels, closing these channels. This causes cell membrane depolarization, opening of voltage-gated calcium channels, calcium influx, and subsequent release of insulin from storage granules. The result is an increase in circulating insulin and a reduction in blood glucose.

C

The safety and efficacy of Dibenol in pediatric patients have not been established. Dibenol is not recommended for use in children, and alternative, better-studied treatments should be considered under pediatric endocrinology or specialist guidance.